NCT02616497 (ASTERIAS) is a Phase 4 clinical trial of Aspirin in Atherothrombosis, sponsored by University of Ioannina.

Who is sponsoring NCT02616497?

NCT02616497 is sponsored by University of Ioannina.

What drugs are being tested in NCT02616497?

Interventions in NCT02616497: Aspirin, Triflusal.

What condition does NCT02616497 study?

NCT02616497 studies Atherothrombosis.

Is NCT02616497 still recruiting?

NCT02616497 is currently completed. Last updated 13 April 2018.

Last reviewed 2018-04-13 · How we verify

NCT02616497: ASTERIAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events

Completed Phase 4 Last updated 13 April 2018

What this trial tests

Phase 4 trial testing Aspirin in Atherothrombosis in 1,220 participants. Completed in 28 March 2018.

Timeline

1 September 2015

Primary endpoint
28 February 2017

28 March 2018

Quick facts

Lead sponsor	University of Ioannina
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	1,220
Start date	1 September 2015
Primary completion	28 February 2017
Estimated completion	28 March 2018
Sites	1 location across Greece

Drugs / interventions tested

Aspirin — full drug profile →
Triflusal (TRIFLUSAL) — full drug profile →

Conditions studied

Atherothrombosis — all drugs for Atherothrombosis →

Sponsor

University of Ioannina

Who can join

18 and older, any sex, with Atherothrombosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Composite of death from vascular causes, myocardial infarction (MI), or stroke (ischaemic or haemorrhagic) during the twelve month treatment period
Time frame: 12 months
Number of participants who suffer from the primary efficacy end point which is the composite of death from vascular causes, myocardial infarction(MI), or stroke during the twelve month treatment period
Rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria during the twelve month treatment period
Time frame: 12 months
Number of participants who suffer from the rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria during the twelve month treatment period

Sponsor's own description

Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Kalantzi KI, Ntalas IV, Chantzichristos VG, Tsoumani ME, et al · · 2019 · cited 5× · PMID 29866011 · DOI 10.2174/1570161116666180605090520

Verify or expand the search:

Other trials of Aspirin

Trials testing the same drug.

NCT07525635 — Aspirin Dosing in Pregnancy · EARLY_PHASE1 · not yet recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
NCT07373756 — Randomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk · Phase 4 · not yet recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06638151 — Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) · Phase 2 · recruiting

Other University of Ioannina trials

Trials by the same sponsor.

NCT07048522 — Perioperative Intravenous Nimodipine Trial · NA · recruiting
NCT06961825 — Brief Title: The Role of Nutrition in the Rehabilitation of Patients With Eating Disorders After a Vascular Stroke. · NA · not yet recruiting
NCT06758518 — Study of the Carpal Tunnel Syndrome in Relation to Stress and Depression Among Medical Students · enrolling by invitation
NCT07164300 — Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery · NA · recruiting
NCT07023497 — Determining the Optimal Dose of Intrathecal Morphine for Post-Cesarean Analgesia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02616497 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Ioannina
Last refreshed: 13 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02616497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing